Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Sotorasib: First Approved KRAS Mutation Inhibitor for the Treatment of Non-small Cell Lung Cancer

Author(s): Surya K. De*

Volume 30, Issue 9, 2023

Published on: 30 September, 2022

Page: [1000 - 1002] Pages: 3

DOI: 10.2174/0929867329666220907161505

Open Access Journals Promotions 2
Next »
[1]
Zhang, S.S.; Nagasaka, M. Spotlight on sotorasib (AMG 510) for KRASG12C positive non-small cell lung cancer. Lung Cancer (Auckl.), 2021, 12, 115-122.
[http://dx.doi.org/10.2147/LCTT.S334623] [PMID: 34675734]
[2]
Hong, D.S.; Fakih, M.G.; Strickler, J.H.; Desai, J.; Durm, G.A.; Shapiro, G.I.; Falchook, G.S.; Price, T.J.; Sacher, A.; Denlinger, C.S.; Bang, Y.J.; Dy, G.K.; Krauss, J.C.; Kuboki, Y.; Kuo, J.C.; Coveler, A.L.; Park, K.; Kim, T.W.; Barlesi, F.; Munster, P.N.; Ramalingam, S.S.; Burns, T.F.; Meric-Bernstam, F.; Henary, H.; Ngang, J.; Ngarmchamnanrith, G.; Kim, J.; Houk, B.E.; Canon, J.; Lipford, J.R.; Friberg, G.; Lito, P.; Govindan, R.; Li, B.T. KRAS G12C inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med., 2020, 383(13), 1207-1217.
[http://dx.doi.org/10.1056/NEJMoa1917239] [PMID: 32955176]
[3]
Canon, J.; Rex, K.; Saiki, A.Y.; Mohr, C.; Cooke, K.; Bagal, D.; Gaida, K.; Holt, T.; Knutson, C.G.; Koppada, N.; Lanman, B.A.; Werner, J.; Rapaport, A.S.; San Miguel, T.; Ortiz, R.; Osgood, T.; Sun, J.R.; Zhu, X.; McCarter, J.D.; Volak, L.P.; Houk, B.E.; Fakih, M.G.; O’Neil, B.H.; Price, T.J.; Falchook, G.S.; Desai, J.; Kuo, J.; Govindan, R.; Hong, D.S.; Ouyang, W.; Henary, H.; Arvedson, T.; Cee, V.J.; Lipford, J.R. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature, 2019, 575(7781), 217-223.
[http://dx.doi.org/10.1038/s41586-019-1694-1] [PMID: 31666701]
[4]
Sproat, M.R.; Hofherr, M.L.; Devarakonda, S. Successful use of sotorasib in a patient with end stage renal disease on dialysis with metastatic lung adenocarcinoma: A case report. Clin. Lung Cancer, 2022, 23(6), E339-E341.
[http://dx.doi.org/10.1016/j.cllc.2022.04.007]
[5]
Ganguly, A.; Yoo, E. Sotorasib: A KRASG12C inhibitor for non-small cell lung cancer. Trends Pharmacol. Sci., 2022, 43(6), 536-537.
[http://dx.doi.org/10.1016/j.tips.2022.03.011] [PMID: 35461718]
[6]
Zheng, X.; Luo, J.; Liu, W.; Ashby, C.R.J., Jr; Chen, Z.S.; Lin, L. Sotorasib: A treatment for non-small cell lung cancer with the KRAS G12C mutation. Drugs Today (Barc), 2022, 58(4), 175-185.
[http://dx.doi.org/10.1358/dot.2022.58.4.3400573] [PMID: 35412531]
[7]
Skoulidis, F.; Li, B.T.; Dy, G.K.; Price, T.J.; Falchook, G.S.; Wolf, J.; Italiano, A.; Schuler, M.; Borghaei, H.; Barlesi, F.; Kato, T.; Curioni-Fontecedro, A.; Sacher, A.; Spira, A.; Ramalingam, S.S.; Takahashi, T.; Besse, B.; Anderson, A.; Ang, A.; Tran, Q.; Mather, O.; Henary, H.; Ngarmchamnanrith, G.; Friberg, G.; Velcheti, V.; Govindan, R. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med., 2021, 384(25), 2371-2381.
[http://dx.doi.org/10.1056/NEJMoa2103695] [PMID: 34096690]
[8]
Awad, M.M.; Liu, S.; Rybkin, I.I.; Arbour, K.C.; Dilly, J.; Zhu, V.W.; Johnson, M.L.; Heist, R.S.; Patil, T.; Riely, G.J.; Jacobson, J.O.; Yang, X.; Persky, N.S.; Root, D.E.; Lowder, K.E.; Feng, H.; Zhang, S.S.; Haigis, K.M.; Hung, Y.P.; Sholl, L.M.; Wolpin, B.M.; Wiese, J.; Christiansen, J.; Lee, J.; Schrock, A.B.; Lim, L.P.; Garg, K.; Li, M.; Engstrom, L.D.; Waters, L.; Lawson, J.D.; Olson, P.; Lito, P.; Ou, S.H.I.; Christensen, J.G.; Jänne, P.A.; Aguirre, A.J. Acquired resistance to KRAS G12C inhibition in cancer. N. Engl. J. Med., 2021, 384(25), 2382-2393.
[http://dx.doi.org/10.1056/NEJMoa2105281] [PMID: 34161704]
[9]
Fakih, M.G.; Kopetz, S.; Kuboki, Y.; Kim, T.W.; Munster, P.N.; Krauss, J.C.; Falchook, G.S.; Han, S.W.; Heinemann, V.; Muro, K.; Strickler, J.H.; Hong, D.S.; Denlinger, C.S.; Girotto, G.; Lee, M.A.; Henary, H.; Tran, Q.; Park, J.K.; Ngarmchamnanrith, G.; Prenen, H.; Price, T.J. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): A prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol., 2022, 23(1), 115-124.
[http://dx.doi.org/10.1016/S1470-2045(21)00605-7] [PMID: 34919824]
[10]
Li, J.X.; Li, R.Z.; Ma, L.R.; Wang, P.; Xu, D.H.; Huang, J.; Li, L.Q.; Tang, L.; Xie, Y.; Leung, E.L.H.; Yan, P.Y. Targeting mutant kirsten rat sarcoma viral oncogene homolog in non-small cell lung cancer: Current difficulties, integrative treatments and future perspectives. Front. Pharmacol., 2022, 13, 875330.
[http://dx.doi.org/10.3389/fphar.2022.875330] [PMID: 35517800]
[11]
Reita, D.; Pabst, L.; Pencreach, E.; Guérin, E.; Dano, L.; Rimelen, V.; Voegeli, A.C.; Vallat, L.; Mascaux, C.; Beau-Faller, M. Direct targeting KRAS mutation in non-small cell lung cancer: Focus on resistance. Cancers (Basel), 2022, 14(5), 1321.
[http://dx.doi.org/10.3390/cancers14051321] [PMID: 35267628]
[12]
Haider, K.; Sharma, A.; Yar, M.S.; Yakkala, P.A.; Shafi, S.; Kamal, A. Novel approaches for the development of direct KRAS inhibitors: Structural insights and drug design. Expert Opin. Drug Discov., 2022, 17(3), 247-257.
[http://dx.doi.org/10.1080/17460441.2022.2029842] [PMID: 35084268]
[13]
Rohatgi, A.; Govindan, R. Targeting KRAS G12C mutation in lung adenocarcinoma. Lung Cancer, 2022, 165, 28-33.
[http://dx.doi.org/10.1016/j.lungcan.2021.12.021] [PMID: 35066360]
[14]
Kwan, A.K.; Piazza, G.A.; Keeton, A.B.; Leite, C.A. The path to the clinic: A comprehensive review on direct KRASG12C inhibitors. J. Exp. Clin. Cancer Res., 2022, 41(1), 27.
[http://dx.doi.org/10.1186/s13046-021-02225-w] [PMID: 35045886]
[15]
Hallin, J.; Engstrom, L.D.; Hargis, L.; Calinisan, A.; Aranda, R.; Briere, D.M.; Sudhakar, N.; Bowcut, V.; Baer, B.R.; Ballard, J.A.; Burkard, M.R.; Fell, J.B.; Fischer, J.P.; Vigers, G.P.; Xue, Y.; Gatto, S.; Fernandez-Banet, J.; Pavlicek, A.; Velastagui, K.; Chao, R.C.; Barton, J.; Pierobon, M.; Baldelli, E.; Patricoin, E.F., III; Cassidy, D.P.; Marx, M.A.; Rybkin, I.I.; Johnson, M.L.; Ou, S.H.I.; Lito, P.; Papadopoulos, K.P.; Jänne, P.A.; Olson, P.; Christensen, J.G. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov., 2020, 10(1), 54-71.
[http://dx.doi.org/10.1158/2159-8290.CD-19-1167] [PMID: 31658955]
[16]
Lanman, B.A.; Allen, J.R.; Allen, J.G.; Amegadzie, A.K.; Ashton, K.S.; Booker, S.K.; Chen, J.J.; Chen, N.; Frohn, M.J.; Goodman, G.; Kopecky, D.J.; Liu, L.; Lopez, P.; Low, J.D.; Ma, V.; Minatti, A.E.; Nguyen, T.T.; Nishimura, N.; Pickrell, A.J.; Reed, A.B.; Shin, Y.; Siegmund, A.C.; Tamayo, N.A.; Tegley, C.M.; Walton, M.C.; Wang, H.L.; Wurz, R.P.; Xue, M.; Yang, K.C.; Achanta, P.; Bartberger, M.D.; Canon, J.; Hollis, L.S.; McCarter, J.D.; Mohr, C.; Rex, K.; Saiki, A.Y.; San Miguel, T.; Volak, L.P.; Wang, K.H.; Whittington, D.A.; Zech, S.G.; Lipford, J.R.; Cee, V.J. Discovery of a covalent inhibitor of KRAS G12C (AMG 510) for the treatment of solid tumors. J. Med. Chem., 2020, 63(1), 52-65.
[http://dx.doi.org/10.1021/acs.jmedchem.9b01180] [PMID: 31820981]
[17]
Ryan, M.B.; Coker, O.; Sorokin, A.; Fella, K.; Barnes, H.; Wong, E.; Kanikarla, P.; Gao, F.; Zhang, Y.; Zhou, L.; Kopetz, S.; Corcoran, R.B. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep., 2022, 39(12), 110993.
[http://dx.doi.org/10.1016/j.celrep.2022.110993] [PMID: 35732135]
[18]
Bon, M.; Bilsland, A.; Bower, J.; McAulay, K. Fragment‐based drug discovery-the importance of high‐quality molecule libraries. Mol. Oncol., 2022. [Online ahead of print]
[http://dx.doi.org/10.1002/1878-0261.13277] [PMID: 35749608]
[19]
Krishnan, T.; Roberts-Thomson, R.; Broadbridge, V.; Price, T. Targeting mutated KRAS genes to treat solid tumours. Mol. Diagn. Ther., 2022, 26(1), 39-49.
[http://dx.doi.org/10.1007/s40291-021-00564-0] [PMID: 34914038]
[20]
Naim, N.; Moukheiber, S.; Daou, S.; Kourie, H.R. KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies. Crit. Rev. Oncol. Hematol., 2021, 168, 103524.
[http://dx.doi.org/10.1016/j.critrevonc.2021.103524] [PMID: 34800654]

Rights & Permissions Print Cite
Article Metrics
48
2
Wayfinder Image
Open Access Journals Promotions
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy